- £66.28bn
- £78.56bn
- £30.33bn
- 87
- 47
- 95
- 92
REG - GSK PLC - Shingrix 18+ at risk China filing review accepted
AnnouncementREG - GSK PLC - FDA accepts Arexvy filing for adults 50-59 at risk
AnnouncementREG - GSK PLC - GSK presents positive DREAMM-7 phase III data
AnnouncementREG - Allianz Global Invs - Top 10 Holdings
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Total Voting Rights
AnnouncementREG - GSK PLC - Statement: Zantac (ranitidine) litigation
AnnouncementREG - GSK PLC - Final Results
AnnouncementREG - GSK PLC - EMA accepts Arexvy filing for adults 50-59 at risk
AnnouncementREG - GSK PLC - European Commission authorises Omjjara in the EU
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - Haleon PLC GSK PLC - Holding(s) in Company
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - GSK completes sale of shares in Haleon plc
AnnouncementREG - GSK PLC - GSK announces intention to sell shares in Haleon
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Nucala approved in China for use in severe asthma
AnnouncementREG - GSK PLC - GSK enters agreement to acquire Aiolos Bio
AnnouncementREG - Allianz Global Invs - Top 10 Holdings
Announcement